BiotechTV - News

Chairman & CEO Sean McCarthy walks us through the science and describes what CytomX has learned about it over many years of working on masking. He discusses the recent EpCAM data, and highlights IFN-α2b and partnered programs.

CEO Jason Coloma walks us through the science that is taking place at the company's South San Francisco headquarters, and descrbies the development programs. The lead program for APOL1-Mediated Kidney Disease is in phase 2, and a second for PKU and Chronic Kidney Disease will have important healthy volunteer proof of concept data this quarter.

President and CEO Jill Milne describes what she believes is the unmet need and profile of Navenibart, and walks us through future anticipated developments. Plus, discussing the company's OX40 antagonist for atopic dermatitis that will have key healthy volunteer proof of concept data in the third quarter of this year.

Founder & CEO Steve Brown, who created CureWise after receiving his own diagnosis of a rare blood cancer, describes his journey and how CureWise is meant to help patients. Its goal is to start with a diversity of opinions from multiple sources and help them converge on a diagnosis.

He discusses the idea behind Syndeio, which focuses on synaptic function and has a lead program in major depressive disorder. Plus, other work he is doing, and Derek's take on the growth and maturity of the biotech ecosystem in Indiana.

CEO Karen Wurster describes the science behind the company, which recently presented proof-of-concept data from human cells at the ADA meeting. Plus, what it is like working from the IBRI in Indianapolis and being an Indiana biotech company.

IBRI CEO Alan Palkowitz descrbies the work that takes place at the IBRI, which includes both the institute's own research and how it acts as an incubator to biotech companies. Plus, the state of biotech in Indiana and what its strengths are here.

Dr. Lamb, a noted expert in neuroscience and Alzheimer's research, introduces us to Stark and describes the investment in people and equipment that has been made here. The institute has two key focuses of 1) modeling Alzheimer's disease and 2) how to expedite research understandings to treat it. Plus, he discusses a company he has co-founded, called Monument Biosciences, that is focusing o...

He highlights his new memoir, Disease Knows No Politics, and gives his opinion on what is at stake in preserving NIH and other scientific funding. Plus, how ModeX is working on multispecifics for cancer and autoimmune conditions, and multivalent vaccines.

He describes how computing power in pathology is augmenting the work that pathologists traditionally do, but also is becoming an increasing important tool in precision medicine.

The company, which recently had a paper earn a spot on the cover of Science, is progressing ahead with both I&I and oncology indications. Dr. Warmuth walks us through the pipeline progress and overall strategy of finding and pursuing targets.

He covers the mechanism of action, this week's efficacy and safety data, what it might mean for the maintenance trial that will read out in 2Q26, additional indications, IP, business development, and more.

She describes Recursion's work, and what the acquisition of Exscientia has brought to the company. Plus, how AI can not only help with drug design, but also safety and patient recruitment.

CEO Sushil Patel walks us through the decisions behind the design of the IGNYTE phase 1/2 study and the ongoing IGNYTE-3 study, he gives Replimune's impression of how the review went since the BLA was filed last November, and he discusses what the CRL could mean for the future.

Amit Etkin says Alto Neuro is trying to use machine learning to understand signals from the complexity of the brain, and the company is also embedding AI in its clinical trials in order to collect as much information from the field as possible. He also walks us through the company's program.

He discusses the importance of interest rates to high risk sectors like biotech, and comment on how our sector has not performed lately like other "risk-on" assets have. Plus, explaining his job of helping CEOs of NYSE listed companies understand the economic and capital markets environment. Note: The NYSE is a sponsor of BiotechTV

Sam Sinai talks about how capsids are being more precisely designed today, which is allowing drug developers to better target them to different organs and to improve their efficiency. Plus, why he believes AI will help make cell and gene therapies reach more patients in the future.

He highlights recent M&A, but also notes how the sector has not been reliant on deals like it has in the past. Plus, discussing how Sarepta's wild ride has not led to contagion, and previewing what key data events are upcoming.

CEO Abbas Kazimi and President of R&D Peter Tummino discuss how AI integrates into their discovery and clinical development work, and walk us through some of the company's current programs.

He describes data that Mestera presented at ADA for its monthly-dosed GLP1 and also its amylin analog. Plus, recent learnings about the field in general, including what orforglipron might mean for the oral therapy space and why Metsera believes in an oral peptide.

CEO Lyn Baranowski describes the therapy and demonstrates the nebulizer that delivers it, and explains how Avalyn's method is designed increase the dose patients can take vs oral therapies and, therefore, increase the therapeutic value.

He discusses the science behind NLRP3, and describes why he thinks NodThera's brain penetration differentiates it from other programs from pharma and other companies. The weight loss program is a oral therapy that doesn't require titration and hasn't shown GI tolerability side effects.

He describes the benefits of prime editing, walks us through human proof-of-concept data that was announced in a patient with Chronic Granulomatous Disease, and explains the rationale to focus on Wilson's Disease, Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis, and the company's CAR-T partnership with Bristol Myers Squibb.

He describes why Kailera chose to in-license a GLP1/GIP specifically, and describes where he sees this asset placing in the competitive landscape based on this data. Plus, commentary on CMC, business development, oral therapies, and more.

He describes the properties that make cyclic peptides unique compared to small molecules and antibodies, and how Curve's approach is different than others in the field. Plus, the work his team is doing on cyclic peptides in their lab at University of Southampton.